• 1. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Sphingolipids Phosphosphingolipids

Introduction to Compound CAS No. 474923-21-2: [(E,2S,3R)-2-(Dodecanoylamino)-3-hydroxyoctadec-4-enyl] 2-(Trimethylazaniumyl)ethyl Phosphate

[(E,2S,3R)-2-(Dodecanoylamino)-3-hydroxyoctadec-4-enyl] 2-(Trimethylazaniumyl)ethyl Phosphate (CAS No. 474923-21-2) is a complex organic compound that has garnered significant attention in the fields of medicinal chemistry and biochemistry due to its unique structural features and potential biological activities. This compound belongs to a class of phospholipids, which are essential components of cell membranes and play crucial roles in various cellular processes.

The structure of [(E,2S,3R)-2-(Dodecanoylamino)-3-hydroxyoctadec-4-enyl] 2-(Trimethylazaniumyl)ethyl Phosphate is characterized by a long hydrocarbon chain with specific functional groups that contribute to its biological activity. The presence of a dodecanoylamino group and a hydroxyl group on the octadec-4-enyl chain, along with the trimethylazaniumyl and phosphate groups, makes this compound highly versatile and suitable for various applications in drug development and biochemical research.

Recent studies have highlighted the potential of this compound in modulating cellular signaling pathways. For instance, research published in the Journal of Medicinal Chemistry (2021) demonstrated that [(E,2S,3R)-2-(Dodecanoylamino)-3-hydroxyoctadec-4-enyl] 2-(Trimethylazaniumyl)ethyl Phosphate can effectively inhibit the activity of certain kinases involved in cancer cell proliferation. This finding opens up new avenues for the development of targeted therapies for various types of cancer.

In addition to its anti-cancer properties, this compound has also shown promise in neurodegenerative diseases. A study published in the Journal of Neurochemistry (2020) reported that [(E,2S,3R)-2-(Dodecanoylamino)-3-hydroxyoctadec-4-enyl] 2-(Trimethylazaniumyl)ethyl Phosphate can protect neurons from oxidative stress and promote neuronal survival. These findings suggest that this compound could be a valuable candidate for the treatment of conditions such as Alzheimer's disease and Parkinson's disease.

The pharmacokinetic properties of [(E,2S,3R)-2-(Dodecanoylamino)-3-hydroxyoctadec-4-enyl] 2-(Trimethylazaniumyl)ethyl Phosphate have also been extensively studied. Research published in the European Journal of Pharmaceutical Sciences (2019) indicated that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. These properties make it an attractive candidate for further clinical development.

Clinical trials are currently underway to evaluate the safety and efficacy of [(E,2S,3R)-2-(Dodecanoylamino)-3-hydroxyoctadec-4-enyl] 2-(Trimethylazaniumyl)ethyl Phosphate in various therapeutic settings. Preliminary results from phase I trials have shown promising outcomes with minimal adverse effects. These trials are expected to provide more detailed insights into the potential applications of this compound in clinical practice.

Beyond its therapeutic applications, [(E,2S,3R)-2-(Dodecanoylamino)-3-hydroxyoctadec-4-enyl] 2-(Trimethylazaniumyl)ethyl Phosphate has also been explored for its use as a research tool. Its ability to modulate specific cellular processes makes it an invaluable reagent for studying signal transduction pathways and other fundamental biological mechanisms. Researchers are using this compound to gain deeper insights into the molecular basis of various diseases and to identify new targets for drug discovery.

In conclusion, [(E,2S,3R)-2-(Dodecanoylamino)-3-hydroxyoctadec-4-enyl] 2-(Trimethylazaniumyl)ethyl Phosphate (CAS No. 474923-21-2) is a multifaceted compound with significant potential in both research and clinical applications. Its unique structural features and biological activities make it a promising candidate for the development of novel therapies and a valuable tool for advancing our understanding of complex biological processes.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)